Scientific publications

Radium-223 in the treatment of bone metastasis in patients with castration-resistant prostate cancer

Orcajo-Rincon J (1), Caresia-Aróztegui AP (2), Del Puig Cózar-Santiago M (3), García-Garzón JR (4), de Arcocha-Torres M (5), Delgado-Bolton RC (6), García-Velloso MJ (7), Alvarez-Ruiz S (8), García-Vicente AM (9).

(1) Servicio de Medicina Nuclear, Hospital General Universitario Gregorio Marañón, Madrid, España.
(2) Servicio de Medicina Nuclear, Hospital Universitari Parc Taulí, Sabadell, Barcelona, España.
(3) Servicio de Medicina Nuclear, ERESA- Hospital General Universitario de Valencia, Valencia, España.
(4) Unitat PET/TC CETIR-ERESA, Esplugues de Llobregat, Barcelona, España.
(5) Unidad de Radiofarmacia, Hospital Universitario Marqués de Valdecilla, Santander, España.
(6) Departamento de Diagnóstico por Imagen y Medicina Nuclear, Hospital San Pedro-Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, La Rioja, España.
(7) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
(8) Servicio de Medicina Nuclear, Hospital Universitario Miguel Servet, Zaragoza, España.
(9) Servicio de Medicina Nuclear, Hospital General Universitario de Ciudad Real, Ciudad Real, España.

Magazine: Revista Española de Medicina Nuclear e Imagen Molecular

Date: Apr 13, 2018

Nuclear Medicine [SP]

ABSTRACT

Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy.

Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease.

It is therefore imperative to define the ideal scenarios and the correct protocol for the use of this therapy and thus offer the greatest possible clinical benefit to the patient.

CITATION  Rev Esp Med Nucl Imagen Mol. 2018 Apr 13. pii: S2253-654X(17)30274-3. doi: 10.1016/j.remn.2018.02.007

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra